Abstract
Fifteen patients from a series of 37 consecutive patients with aggressive NHL who achieved a complete remission (CR) with first line chemotherapy were defined at high or high-intermediate risk of relapse according to International Prognostic Risk Index and were treated with αIFN as maintenance therapy for two years. After a median follow-up of 62 months only 3/15 patients (20%) relapsed and 2/15 (13.3%) died in the αIFN treated group, favourably comparing with the expected relapse and death rate in that setting; on the other hand 40.9% of 'low risk' patients from the same series, who did not receive αIFN, had relapsed. αIFN maintenance therapy appears to result in prolonged response duration and survival in patients with aggressive and prognostically unfavourable NHL.
| Original language | English |
|---|---|
| Pages (from-to) | 733-735 |
| Number of pages | 3 |
| Journal | Oncology Reports |
| Volume | 3 |
| Issue number | 4 |
| Publication status | Published - 1996 |
Fingerprint
Keywords
- aggressive non-Hodgkin's lymphoma
- alpha-interferon
- prognostic factors
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Maintenance therapy with recombinant interferon alpha-2B (αIFN) in prognostically unfavourable aggressive non-Hodgkin's lymphomas (NHL). / Palmieri, G.; Morabito, A.; Rea, A.; Lauria, R.; Montesarchio, V.; Biondi, E.; Caraglia, M.; Tagliaferri, P.; Blanco, A. R.
In: Oncology Reports, Vol. 3, No. 4, 1996, p. 733-735.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Maintenance therapy with recombinant interferon alpha-2B (αIFN) in prognostically unfavourable aggressive non-Hodgkin's lymphomas (NHL)
AU - Palmieri, G.
AU - Morabito, A.
AU - Rea, A.
AU - Lauria, R.
AU - Montesarchio, V.
AU - Biondi, E.
AU - Caraglia, M.
AU - Tagliaferri, P.
AU - Blanco, A. R.
PY - 1996
Y1 - 1996
N2 - Fifteen patients from a series of 37 consecutive patients with aggressive NHL who achieved a complete remission (CR) with first line chemotherapy were defined at high or high-intermediate risk of relapse according to International Prognostic Risk Index and were treated with αIFN as maintenance therapy for two years. After a median follow-up of 62 months only 3/15 patients (20%) relapsed and 2/15 (13.3%) died in the αIFN treated group, favourably comparing with the expected relapse and death rate in that setting; on the other hand 40.9% of 'low risk' patients from the same series, who did not receive αIFN, had relapsed. αIFN maintenance therapy appears to result in prolonged response duration and survival in patients with aggressive and prognostically unfavourable NHL.
AB - Fifteen patients from a series of 37 consecutive patients with aggressive NHL who achieved a complete remission (CR) with first line chemotherapy were defined at high or high-intermediate risk of relapse according to International Prognostic Risk Index and were treated with αIFN as maintenance therapy for two years. After a median follow-up of 62 months only 3/15 patients (20%) relapsed and 2/15 (13.3%) died in the αIFN treated group, favourably comparing with the expected relapse and death rate in that setting; on the other hand 40.9% of 'low risk' patients from the same series, who did not receive αIFN, had relapsed. αIFN maintenance therapy appears to result in prolonged response duration and survival in patients with aggressive and prognostically unfavourable NHL.
KW - aggressive non-Hodgkin's lymphoma
KW - alpha-interferon
KW - prognostic factors
UR - http://www.scopus.com/inward/record.url?scp=0029977339&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029977339&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0029977339
VL - 3
SP - 733
EP - 735
JO - Oncology Reports
JF - Oncology Reports
SN - 1021-335X
IS - 4
ER -